Search

Daledalin

Daledin (UK-3557-15) is a selective norepinephrine reuptake inhibitor. It has no effects on the reuptake of serotonin or dopamine, and no antihistamine or anticholinergic properties. … It was in trials for depression in the 1970s but never marketed.

Ebola Zaire vaccine (live, attenuated)

[L10866] In 2014, Merck Inc. signed a licensing agreement with NewLink for further development and marketing. … [L10854] By introducing the relatively inactive viral protein to the patient, the patient’s immune system learns to recognize and attack the virus if he or she is exposed to it in the future.

Lemborexant

[L10863] Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits, but rather an inability to … Lemborexant is a novel dual orexin receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.

Calcium phosphate dihydrate

Pentoxyverine

It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists [A32160]. … Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant [A32717], and local anesthetic properties.

Alclofenac

Alclofenac is a non-steroidal anti-inflammatory drug. It was withdrawn from the market in the United Kingdom in 1979.

mRNA-1283

[L53413,A274083] mNEXSPIKE was approved by the US FDA in June 2025 for use in patients who have been previously vaccinated with any COVID-19 vaccine and who are at a higher risk of severe outcomes from … 2 spike protein, allowing for a more targeted immune response and the use of a significantly smaller amount of mRNA per dose.

Bendroflumethiazide

A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders.

Omidenepag isopropyl

[A253253] In 2018, omidenepag isopropyl was approved in Japan for the treatment of glaucoma and ocular hypertension.[A253268] In September 2022, the FDA approved the use of omidenepag isopropyl. … [A253263,A253268] Prostanoid FP receptor agonists (FP agonists), such as [latanoprost], are part of the first-line therapy for ocular hypertension and primary open-angle glaucoma; however, not all patients

Acenocoumarol

This prevents carboxylation of vitamin K-dependent clotting factors, II, VII, IX and X, and interferes with coagulation. … Patients on acenocoumarol are prohibited from giving blood.